Staidson (Beijing) Biopharmaceuticals Co Ltd
300204
Company Profile
Business description
Staidson (Beijing) Biopharmaceuticals Co Ltd is a pharmaceutical company mainly engaged in the research, development, production, and sale of biological products in China. Its products include mouse nerve growth factor injection, intravenous compound polyethylene glycol electrolyte powder solution, gliclazide, nabumetone, and aspirin.
Contact
Rongjing Dong Street
No 5 Beijing Economic and Technological Development Zone
Beijing100176
CHNT: +86 1067862266
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
492
Stocks News & Analysis
stocks
ASX healthcare giant remains well positioned despite share slump
We welcome the CEO change at CSL but relatively soft plasma performance will postpone recovery
stocks
Australian bank remains overvalued despite strong result
When strong fundamentals meet persistent valuation headwinds.
stocks
Chart of the Week: Soft earnings growth outlook for Australian banks
The latest take from our equity research analysts.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,281.80 | 41.30 | -0.44% |
| CAC 40 | 8,313.24 | 14.64 | -0.18% |
| DAX 40 | 24,856.15 | 131.70 | -0.53% |
| Dow JONES (US) | 50,121.40 | 66.74 | -0.13% |
| FTSE 100 | 10,472.11 | 118.27 | 1.14% |
| HKSE | 27,070.18 | 196.20 | -0.72% |
| NASDAQ | 23,066.47 | 36.01 | -0.16% |
| Nikkei 225 | 57,695.67 | 45.13 | 0.08% |
| NZX 50 Index | 13,531.48 | 24.20 | 0.18% |
| S&P 500 | 6,941.47 | 0.34 | -0.00% |
| S&P/ASX 200 | 9,043.50 | 18.50 | -0.20% |
| SSE Composite Index | 4,136.59 | 4.61 | 0.11% |